September 13, 2012
Bayer HealthCare of Germany announced on September 11 that Bayer Yakuhin had filed a new drug application (NDA) at the end of July for the oral multi-kinase inhibitor regorafenib (generic name) for the indication of unresectable, advanced/recurrent colorectal cancer (CRC),...read more